Patents Assigned to TRON—Translationale Onkologie An Der Universitätsmedizín Der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
-
Patent number: 11713346Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.Type: GrantFiled: May 9, 2016Date of Patent: August 1, 2023Assignees: BioNTech Cell & Gene Therapies GmbH, TRON—Translationale Onkologie An Der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
-
Patent number: 11701413Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.Type: GrantFiled: April 10, 2018Date of Patent: July 18, 2023Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Sebastian Kreiter, Christina Krienke, Jutta Petschenka, Lena Mareen Kranz, Mustafa Diken
-
Patent number: 11541127Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: April 13, 2016Date of Patent: January 3, 2023Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
-
Patent number: 11471522Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.Type: GrantFiled: March 21, 2018Date of Patent: October 18, 2022Assignees: BIONTECH SE, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBHInventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
-
Patent number: 11279757Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.Type: GrantFiled: September 5, 2018Date of Patent: March 22, 2022Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbhInventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
-
Patent number: 11168337Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5? replication recognition sequence, wherein the 5? replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5? replication recognition sequence.Type: GrantFiled: March 13, 2017Date of Patent: November 9, 2021Assignees: Moniech RNA Pharmecenticais GmbH, TRON—Translationale Onkologie An Der Universitätsmedizín Der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Tim Beissert, Ugur Sahin, Mario Perkovic
-
Patent number: 10596256Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.Type: GrantFiled: December 21, 2015Date of Patent: March 24, 2020Assignees: TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH, ASTELLAS PHARMA INC.Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Rita Mitnacht-Kraus
-
Patent number: 9512232Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.Type: GrantFiled: May 6, 2013Date of Patent: December 6, 2016Assignees: GANYMED PHARMACEUTICALS AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll